Shares of KalVista Pharmaceuticals (NASDAQ: KALV) soared 115% on Tuesday after the pharmaceutical company released promising results from its phase 2 clinical trial for KVD900, its oral drug for hereditary angioedema (HAE) attacks.
KalVista's study showed that 15% of the patients who were treated with KVD900 within one hour of experiencing a swelling attack required rescue medication, compared to 30% of those who received a placebo. KVD900 also appeared to be generally safe and well-tolerated, with no serious adverse events reported.
KalVista Pharmaceuticals' stock price surged on Tuesday. Image source: Getty Images.
For further details see:
Why KalVista Pharmaceuticals Stock Skyrocketed 115% Today